Lenvatinib/Everolimus Approved for Use in Advanced Kidney Cancer After Antiangiogenic Therapy

被引：0
|
作者：
Schuyler, Devon
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：416 / 416
页数：1
相关论文
共 50 条
  • [31] Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma
    Junichi Shindoh
    Yusuke Kawamura
    Masahiro Kobayashi
    Norio Akuta
    Satoshi Okubo
    Masaru Matsumura
    Yoshiyuki Suzuki
    Masaji Hashimoto
    Journal of Gastrointestinal Surgery, 2022, 26 (8) : 1637 - 1646
  • [32] Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma
    Shindoh, Junichi
    Kawamura, Yusuke
    Kobayashi, Masahiro
    Akuta, Norio
    Okubo, Satoshi
    Matsumura, Masaru
    Suzuki, Yoshiyuki
    Hashimoto, Masaji
    JOURNAL OF GASTROINTESTINAL SURGERY, 2022, 26 (08) : 1637 - 1646
  • [33] Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy
    Ohya, Yuki
    Hayashida, Shintaro
    Tsuji, Akira
    Kuramoto, Kunitaka
    Shibata, Hidekatsu
    Setoyama, Hiroko
    Hayashi, Hironori
    Kuriwaki, Kazumi
    Sasaki, Masato
    Iizaka, Masayoshi
    Nakahara, Osamu
    Inomata, Yukihiro
    SURGICAL CASE REPORTS, 2020, 6 (01)
  • [34] Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy
    Yuki Ohya
    Shintaro Hayashida
    Akira Tsuji
    Kunitaka Kuramoto
    Hidekatsu Shibata
    Hiroko Setoyama
    Hironori Hayashi
    Kazumi Kuriwaki
    Masato Sasaki
    Masayoshi Iizaka
    Osamu Nakahara
    Yukihiro Inomata
    Surgical Case Reports, 6
  • [35] Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant
    Malvezzi, Paolo
    Jouve, Thomas
    Rostaing, Lionel
    Experimental and Clinical Transplantation, 2016, 14 (04) : 361 - 366
  • [36] Teriparatide Replacement Therapy for Hypoparathyroidism During Treatment With Lenvatinib for Advanced Thyroid Cancer: A Case Report
    Porcelli, Tommaso
    Sessa, Francesca
    Caputo, Angela
    Catalini, Christian
    Salvatore, Domenico
    FRONTIERS IN ENDOCRINOLOGY, 2018, 9
  • [37] Incidence and implications of pseudoprogression in women with advanced or recurrent endometrial cancer on pembrolizumab/lenvatinib combination therapy
    Ackroyd, Sarah
    Knickerbocker, Abbey
    Rodriguez, Gustavo
    Lippitt, Melissa
    Moore, Elena Diaz
    Vogel, Tilley Jenkins
    GYNECOLOGIC ONCOLOGY, 2023, 173 : S19 - S19
  • [38] Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer
    Wang, Yunchao
    Xun, Ziyu
    Yang, Xu
    Wang, Yanyu
    Wang, Shanshan
    Xue, Jingnan
    Zhang, Nan
    Yang, Xiaobo
    Lu, Zhenhui
    Zhou, Jinxue
    Zhou, Kang
    Sang, Xinting
    Zhao, Haitao
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (03): : 1026 - +
  • [39] Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
    Liu, Yu-Tao
    Hao, Xue-Zhi
    Li, Jun-Ling
    Hu, Xing-Sheng
    Wang, Yan
    Wang, Zi-Ping
    Wang, Hong-Yu
    Wang, Bin
    Han, Xiao-Hong
    Zhang, Xiang-Ru
    Shi, Yuan-Kai
    THORACIC CANCER, 2015, 6 (05) : 636 - 642
  • [40] Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
    Kwok, Christopher
    Khorasanchi, Adam
    Psutka, Sarah P.
    Hinkley, Megan
    Dason, Shawn
    Sundi, Debasish
    Yang, Yuanquan
    Yang, Yajing
    Verschraegen, Claire
    Gross, Evan E.
    Orcutt, Delaney
    Yin, Ming
    FRONTIERS IN ONCOLOGY, 2023, 13
12345